Literature DB >> 19911030

Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii.

Jun-Chang Cui1, You-Ning Liu, Liang-An Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19911030     DOI： 10.1038/ja.2009.111

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  8 in total

Review 1.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

2.  Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.

Authors:  Q Mei; Y Ye; Y-L Zhu; J Cheng; X Chang; Y-Y Liu; H-R Li; J-B Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-26       Impact factor: 3.267

3.  Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.

Authors:  Chengchun Sun; Junwen Hao; Meiqin Dou; Yanwen Gong
Journal:  J Antibiot (Tokyo)       Date:  2014-11-05       Impact factor: 2.649

4.  Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.

Authors:  C K Hesje; K Drlica; J M Blondeau
Journal:  J Antimicrob Chemother       Date:  2014-10-16       Impact factor: 5.790

5.  Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.

Authors:  Ai-Jun Pan; Qing Mei; Ying Ye; Hong-Ru Li; Bao Liu; Jia-Bin Li
Journal:  J Antibiot (Tokyo)       Date:  2016-10-19       Impact factor: 2.649

6.  Prescription Patterns for Tigecycline in Severely Ill Patients for Non-FDA Approved Indications in a Developing Country: A Compromised Outcome.

Authors:  Rima A Moghnieh; Dania I Abdallah; Ismail A Fawaz; Tarek Hamandi; Mohammad Kassem; Nabila El-Rajab; Tamima Jisr; Anas Mugharbil; Nabila Droubi; Samaa Al Tabah; Loubna Sinno; Fouad Ziade; Ziad Daoud; Ahmad Ibrahim
Journal:  Front Microbiol       Date:  2017-03-27       Impact factor: 5.640

7.  Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.

Authors:  Joseph M Blondeau; Shantelle D Fitch
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

8.  Nisin Influence on the Antimicrobial Resistance Ability of Canine Oral Enterococci.

Authors:  Eva Cunha; Rita Janela; Margarida Costa; Luís Tavares; Ana Salomé Veiga; Manuela Oliveira
Journal:  Antibiotics (Basel)       Date:  2020-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.